Top Stocks
U.S. Stock Market Overview
Top Analyst Stocks
Top Smart Score Stocks
Top Insiders Stocks
Popular
Stock Screener
Top Online Growth Stocks
Trending Stocks
Penny Stock Screener
Dividend Investing
Dividend Calculator
Dividend Yield Calculator
Dividend Stocks
Dividend News
Dividend Calendar
ETFs
Top ETFs by AUM
SPY ETF
QQQ ETF
Stock Comparison
Energy Stocks
Oil Stocks
Best Value Stocks
Airline Stocks
Electric Vehicle Stocks
MATANA Stocks
New
Bank Stocks
Compare More Stocks…
Calendars
IPO Calendar
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
Market Holidays
Daily Analyst Ratings
Daily Insider Trading
Research Tools
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Stock Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
News
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
My Watchlist
Smart Portfolio
About Us
About TipRanks
Contact Us
Working with TipRanks
Enterprise Solutions
Tools for Trading Platforms
Data for Hedge Funds
Best Online Brokers
Become an Affiliate
Follow Us
More
Plans
News
Smart Portfolio
Expert Center
Ideas
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed Tools
Try Now
Top Stocks
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Top Experts
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Research Tools
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Comparisons
Stock Comparison
POPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
Smart Portfolio
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Calendars
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
News
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About Us
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing
EDIT
Stock Latest News
The Fly
Editas Medicine initiated with an Overweight at Cantor Fitzgerald
3d ago
EDIT
Press Releases
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
15d ago
EDIT
The Fly
Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech
15d ago
EDIT
The Fly
Editas Medicine provides update, to reduce headcount by approximately 20%
25d ago
EDIT
Press Releases
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
25d ago
EDIT
Press Releases
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
30d ago
EDIT
The Fly
Editas Medicine initiated with a Neutral at Citi
2M ago
EDIT
The Fly
Editas Medicine to host conference call
2M ago
EDIT
The Fly
Editas Medicine’s EDIT-301 shows safety and efficacy in sickle cell disease
2M ago
EDIT
Press Releases
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
2M ago
EDIT
The Fly
Editas Medicine to host conference call
2M ago
EDIT
The Fly
Editas Medicine to host conference call
2M ago
EDIT
The Fly
Editas Medicine assumed with a Neutral at Credit Suisse
2M ago
EDIT
Press Releases
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
2M ago
EDIT
Press Releases
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
3M ago
EDIT
Press Releases
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
3M ago
EDIT
Press Releases
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
4M ago
EDIT
Press Releases
Editas Medicine to Participate in Upcoming Investor Conferences
5M ago
EDIT
Stock Analysis & Ideas
Editas Medicine: Here’s What Might Trigger More Downside
6M ago
EDIT
Press Releases
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
6M ago
EDIT
Press Releases
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
6M ago
EDIT
Press Releases
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
7M ago
EDIT
Market News
Editas Gains 10.1% as Q4 Results Surpass Estimates
11M ago
EDIT
You need to enable JavaScript to run this app.
